RE: Great posts from9 Apr 2024 09:06
Perhaps, we will see. The valuation here seems absurd to me. By my estimations they have more cash on hand than the MCAP. They have several deals in place with billions in potential earnings. The risk is somewhat mitigated by the number of molecules in clinic. The free float is extremely low, in what is already a low MCAP stock. Who is going to be selling at this price? So, in summary I don't see any sellers (assuming institutions are done) and a small amount of buying, based on great value, will put a rocket under this.